併用療法
“Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors”. Cell Reports 6 (2): 377–387. doi:10.1016/j.celrep.2013.12.035. ISSN 2211-1247. PMC 4409143. PMID 24440717. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409143/.
↑ Musgrove, Elizabeth A.; Caldon, C. Elizabeth; Barraclough, Jane; Stone, Andrew; Sutherland, Robert L. (2011-07-07). “Cyclin D as a therapeutic target in cancer”. Nature Reviews. Cancer 11 (8): 558–572. doi:10.1038/nrc3090. ISSN 1474-1768. PMID 21734724.
↑ “Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer | Novartis US” (英語). www.pharma.us.novartis.com.
2017年10月4日時点のオリジナルよりアーカイブ。2017年10月3日閲覧。
↑ Korkut, A; Wang, W; Demir, E; Aksoy, BA; Jing, X; Molinelli, EJ; Babur, Ö; Bemis, DL et al. (18 August 2015). “Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.”. eLife 4. doi:10.7554/elife.04640. PMC 4539601. PMID 26284497. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539601/.
↑ Lee, MJ; Ye, AS; Gardino, AK; Heijink, AM; Sorger, PK; MacBeath, G; Yaffe, MB (11 May 2012). “Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.”. Cell 149 (4): 780–94. doi:10.1016/j.cell.2012.03.031. PMC 3501264. PMID 22579283. https://www.